← Back to Search

Resiliency Training for Neurofibromatosis

N/A
Waitlist Available
Led By Ana-Maria Vranceanu, PhD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Has a diagnosis of NF1 or NF2 and is between the ages of 12-17
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 weeks, 8 weeks, 6 months,12 months
Awards & highlights

Study Summary

This trial is testing two stress and symptom management programs for adolescents with Neurofibromatosis 1 and 2. The programs are 8 weeks long and done in a group setting.

Who is the study for?
Adolescents aged 12-17 with Neurofibromatosis type 1 or 2, who can understand and consent to the study in English with parental approval. Participants should have difficulties managing stress and NF symptoms but no major unrelated medical issues, recent changes in antidepressants, or recent cognitive therapy.Check my eligibility
What is being tested?
The trial is testing two different resiliency training programs delivered through live video over eight weeks to see how they help adolescents with Neurofibromatosis manage stress and symptoms related to their condition.See study design
What are the potential side effects?
Since the interventions are non-medical stress management programs, there may not be direct side effects like those associated with medications; however, participants might experience emotional discomfort while discussing personal topics.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am diagnosed with NF1 or NF2 and am between 12-17 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 weeks, 8 weeks, 6 months,12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 weeks, 8 weeks, 6 months,12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Physical Health Quality of Life
Change in Psychological Health Quality of Life
Secondary outcome measures
Anxiety
Depression
Environmental Quality of Life
+3 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Stress and Symptom Management Program 1Experimental Treatment1 Intervention
Group II: Stress and Symptom Management 2Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,944 Previous Clinical Trials
13,203,511 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis
United States Department of DefenseFED
869 Previous Clinical Trials
327,502 Total Patients Enrolled
1 Trials studying Neurofibromatosis
19 Patients Enrolled for Neurofibromatosis
Ana-Maria Vranceanu, PhDPrincipal Investigator - Massachusetts General Hospital
Massachusetts General Hospital
20 Previous Clinical Trials
1,886 Total Patients Enrolled
2 Trials studying Neurofibromatosis
151 Patients Enrolled for Neurofibromatosis

Media Library

Stress and Symptom Management Program 1 Clinical Trial Eligibility Overview. Trial Name: NCT03873610 — N/A
Neurofibromatosis Research Study Groups: Stress and Symptom Management Program 1, Stress and Symptom Management 2
Neurofibromatosis Clinical Trial 2023: Stress and Symptom Management Program 1 Highlights & Side Effects. Trial Name: NCT03873610 — N/A
Stress and Symptom Management Program 1 2023 Treatment Timeline for Medical Study. Trial Name: NCT03873610 — N/A
~37 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top